Pharmacological inhibition of USP8/AKT alleviates MDA5‐driven autoimmunity, demonstrating the USP8‐MDA5 axis as a therapeutic target for autoimmune disorders linked to aberrant MDA5 activation. This evidence concerns the gene IFIH1 and autoimmune disease.